Every Form 4 that Obsidian Therapeutics, Inc. (OBX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OBX filings page.
Obsidian Therapeutics, Inc. granted Chief Executive Officer Madan Jagasia a stock option covering 37,653 shares of common stock on August 3, 2026. The option has an exercise price of $12.00 per share and expires on August 2, 2036. The underlying 37,653 shares vest and become exercisable upon the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders following the grant date, subject to Dr. Jagasia’s continued service.
Barrett Peter reported acquisition or exercise transactions in this Form 4 filing.
Obsidian Therapeutics, Inc. director Peter Barrett received a grant of stock options for 37,653 shares of common stock, exercisable at $12.00 per share. These options expire on August 2, 2036 and represent his entire reported derivative holding after the grant. The options vest and become exercisable upon the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders, conditioned on his continued service.
Obsidian Therapeutics, Inc. director Heidi Hagen received a stock option grant covering 37,653 shares of common stock on 2026-08-03. The option has an exercise price of $12.00 per share and expires on 2036-08-02. The shares vest upon the earlier of the one-year anniversary of the grant date or the company’s next annual stockholders’ meeting, subject to her continued service.
Obsidian Therapeutics, Inc. director Maria Fardis received a compensatory stock option grant for 37,653 shares of common stock on August 3, 2026. The option has an exercise price of $12.00 per share and expires on August 2, 2036. The shares underlying this option vest and become exercisable upon the earlier of the one-year anniversary of the grant date or the issuer's annual meeting of stockholders following the grant date, subject to her continued service.